Drug Profile
Research programme: voltage-gated potassium channels - Correvio Pharma
Alternative Names: Kv 1.5 channel blockers - Cardiome; Voltage-gated potassium channels research programme - Correvio PharmaLatest Information Update: 01 Jun 2020
Price :
$50
*
At a glance
- Originator Cardiome Pharma
- Class
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 27 May 2020 Correvio Pharma has been acquired by ADVANZ PHARMA
- 15 May 2018 Cardiome Pharma is now called Correvio Pharma
- 14 Sep 2004 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)